Dear Sir,

Even though the coronavirus disease 2019 (COVID-19) affects primarily the respiratory system some reports describe nervous system involvement as well \[[@CR1]--[@CR3]\]. Headache and anosmia have been frequently described as neurological symptoms of mild-to-moderate COVID-19 but a direct impact of COVID-19 on neuronal integrity has not been clarified yet \[[@CR4]\]. Therefore, a neuronal biomarker would be extremely useful to elucidate neuro-axonal injury during an infection with Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and in the post-infection follow-up period. Serum neurofilament light chain (sNfL) has recently been considered as a specific biomarker to quantitate neuro-axonal damage in several disorders of the peripheral and central nervous system \[[@CR5]\]. Hence, sNfL might also serve as a sensitive screening and follow-up marker for neuronal injury in COVID-19 patients.

We conducted a prospective cohort study in 100 healthcare workers (84 females, 16 males) following a COVID-19 outbreak in a major German children\'s and women\'s hospital \[[@CR6]\]. The Ethics Committee of the University of Regensburg approved the study (file-number: 20-1767-101), and written informed consent was obtained from all study participants. They were categorized according to their SARS-CoV-2 infection status, *n* = 28 tested positive, *n* = 72 negative in PCR-based viral RNA amplification from nasopharyngeal swabs (Xpert© Xpress SARS-CoV-2, Cepheid) \[[@CR5]\]. To preserve anonymity of study participants, age was assessed in three categories (18--35 years *n* = 33, 36--50 years *n* = 37 and 51--65 years *n* = 30) \[[@CR7]\]. sNfL concentrations were measured using the single molecule array (Simoa) NF-light^®^ kit on the HD-X Analyzer (Quanterix, Lexington, MA) \[[@CR5]\]. First, descriptive statistics were calculated. Then, a multivariable linear regression model was fitted with sNfL as dependent variable and with sex, age and COVID-19 status as independent variables.

All COVID-19 patients had mild-to-moderate symptoms and recovered after 1--3 weeks and showed no or only minor neurological symptoms, including anosmia and headache. First, sNfL measurement was done in COVID-19 patients 23 days (median, IQR 21--26) after onset of disease. sNfL levels for COVID-19 patients and for controls, stratified for age group, are depicted in Fig. [1](#Fig1){ref-type="fig"}. Median and interquartile range for COVID-19 patients were 4.5 pg/ml \[IQR 3.7--5.7\] for the age group 18--35 years, 9.6 \[6.5--11.3\] for the age group 36--50 years, and 11.6 \[8.4--18.3\] for the age group 51--65 years, respectively. sNFL levels for controls were 4.4 \[3.5--5.5\] for the youngest group, 6.8 \[5.6--8.8\] for the group 36--50 years, and 9.6 \[8.2--11.2\] for the oldest group (Table [1](#Tab1){ref-type="table"}). Fig. 1Boxplots of sNfL concentrations in COVID-19 and control cases stratified by age group. Of note, COVID-19 status (*p* = 0.005) and age group (*p* \< 0.001) are significantly associated with sNfL values in a multivariable linear regression analysis of sex, age and COVID-19 statusTable 1Baseline characteristics of study participants stratified by COVID-19 statusNon COVID-19 (*n* = 72)COVID-19 (*n* = 28)Female (*N*, %)59 (81.9)25 (89.3)Male (*N*, %)13 (18.1)3 (10.7)Age group 18--35 years (*N*, %)20 (27.7)13 (46.4)Age group 36--50 years (*N*, %)28 (38.9)9 (32.14)Age group 51--65 years (*N*, %)24 (33.3)6 (21.4)Respiratory symptoms (*N*, %)17 (60.7)Neurological symptoms (*N*, %)21 (75.0)Notes: respiratory symptoms included cough and shortness of breath; neurological symptoms included headache and anosmia

Since sNFL levels are highly dependent on age \[[@CR8]\] the association between COVID-19 status and sNFL was determined using a multivariable linear regression model with COVID-19 status, age and sex as independent variables. This analysis revealed that COVID-19 status was significantly associated with sNfL (*b* = 1.87; *p* = 0.005) when controlling for age and sex (Table [2](#Tab2){ref-type="table"}). In COVID-19 patients with two sNfL measurements (*n* = 16, time span between the measurements was median 35 days, range 29--36 days), sNfL levels were highly correlated (*r* = 0.96).Table 2Multivariable linear regression analysis of sex, age and COVID-19 status on sNfL*b*SE B*βp*Sex (female)− 0.020.84− 0.000.981Age group 18--35 yearsReference categoryAge group 36--50 years3.380.720.44\< 0.001Age group 51--65 years6.100.740.76\< 0.001COVID-191.870.650.230.005Notes: *n* = 100. Nagelkerke's *R*^2^ = 0.45; *b* regression coefficient, *SE B* standard error (regression coefficient), *β* standardized regression coefficient, *p* significance value

NfL is a highly specific structural protein of neurons and elevated levels of sNfL are recognized as measures of acute or chronic neuro-axonal damage \[[@CR5]\]. Our results from a study in health care workers without known co-morbidities indicate that mild-to-moderate COVID-19 is associated with increased sNfL levels. Neurologic symptoms and complications in patients with SARS-CoV-2 infection have been reported by the first available studies during SARS-CoV-2 pandemic \[[@CR1], [@CR2]\]. However, these studies are restricted to hospitalized patients and, therefore, represent a population more likely to have severe neurological manifestations for a variety of reasons. Our results indicate for the first time that COVID-19 may affect the neuro-axonal integrity also in adults with a mild-to-moderate course of the disease. This new evidence for a more general neuro-destructive capability of SARS-CoV-2 also in mild-to-moderate COVID-19 patients should raise awareness for potential long-term neurologic sequelae following COVID-19. Of note, our study includes only a limited number of patients. In addition, information on participants' age was collected using very broad categories and we cannot exclude that there were age differences between COVID-19 patients and controls not accounted for in the statistical adjustment using age groups. To draw further conclusions, additional studies on sNfL and COVID-19 are needed.
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